Furthermore, some previous longitudinal studies have shown that the circulating adiponectin level predicts subsequent changes in insulin resistance and the incidence of T2DM within several years (Choi et al. 2004; Yamamoto et al. 2004), suggesting that the adiponectin level could be useful as a biomarker that reflects the future risk of T2DM onset. Here, ADIPOQ is linked to Insulin resistance.